Small molecule (NCE) agonist of sigma1 receptor for the treatment of several neurodegenerative diseases. 2 chemical series, protected by 2 patents, highly selective and affine. Preliminary in-vivo data available on Alzheimer's, ALS (amyotrophic lateral sclerosis) and CIAS (cognitive impairement associated with schizophrenia) models.

Dermapol is an innovative tool which helps skin pathologies diagnosis, such as melanoma. Detecting a polarimetric signature of pathologic tissues, it brings a considerable and objective help to practitioners. Dermapol device is portable and miniaturised. Currently under clinical study.

This project aims at increasing the therapeutic window of ADCs by developing a linker that releases the payload selectively in cancerous cells.
Using cytometric screening technology, we identified a new linker with unprecedented selectivity for cancer cells which express specific enzymes.

An anti-counterfeiting solution which can be formulated in different matrixes and integrated in marking solutions, such as printing inks. DualEm is a fluorescent molecular structure emitting at 2 specific wavelengths under UV and keeping this capacity at liquid and solid state. The dual emission fingerprint depends on the formulation used, very difficult to counterfeit

Thanks to the introduction of two different dynamic chemical groups into a polymeric network, this technology brings interesting properties to thermosetting materials, such as better recyclibility, self-healing under heat or solvent action and reversible adhesion to easily detach thermoset materials.

Development of new photopolymerisable formulations (under UV or near-infrared LED light) for epoxy-amines resins. These formulations allow a polymerisation within minutes instead of hours, at room temperature without the necessity of thermal cure. Their application is in various fields and markets, such as composites, adhesives etc.

Restoring apelin signaling in sarcopenia considerably enhanced muscles’ function and regenerative capacity. GlucoFAP13 project proposes apelin-13 derivatives stabilized by an innovative technology. Evaluation ongoing for efficacy in improving muscle strength, stamina and endurance in a sarcopenic mouse model.

News targets and gene therapy approaches to treat centronuclear myopathies. 2 proteins identified as relevant targets for the different forms of centronuclear myopathies (XL-CNM and AD-CNM). We propose a patents portfolio covering these targets for CNM treatment, based on solid and published proof of concept.

New antibody fragments for the treatment of thrombosis (stroke, thrombotic purpura, coronary syndrome...). Our approach is directed against a platelet receptor that is not currently targeted by commercially available products, and prevents thrombus formation with a reduced bleeding risk.

A numerical simulation software and plug-in for the training of surgeons including real haptic sensations. The developed method stimulates organs and medical devices for a realistic impression. The latest developments already allowed its application in needle insertion in human tissues and directly in the training of kidney stones removal.